Infect Chemother.  2009 Apr;41(2):65-71. 10.3947/ic.2009.41.2.65.

Antifungal Resistance in Yeasts and Filamentous Fungi

• Shin JH

• KMID: 2170252
• DOI: http://doi.org/10.3947/ic.2009.41.2.65

Abstract

The incidence of invasive fungal infection has increased worldwide along with the increasing population of high risk patients. Recently developed antifungal agents, such as second-generation triazoles and echinocandins, provide the potential to improve therapeutic options against invasive fungal infections. However, treatment of invasive fungal infections has been hampered by both intrinsic and acquired resistance to antifungal agents among many fungal pathogens. A better understanding of the clinical impact of antifungal resistance is important for selecting the proper antifungal agent in patients with systemic fungal infections. This article reviews the current situation with regard to intrinsic and acquired resistance of clinically significant yeasts and filamentous fungi against currently available antifungal agents.

Keyword

Antifungal drug resistance; Azoles; Echinocandins; Amphotericin B; Filamentous fungi

MeSH Terms

Amphotericin B
Antifungal Agents
Azoles
Drug Resistance, Fungal
Echinocandins
Fungi
Humans
Incidence
Triazoles
Yeasts
Amphotericin B
Antifungal Agents
Azoles
Echinocandins
Triazoles

Reference

1. Arikan S, Rex JH. Murray PR, Baron EJ, Jorgensen JH, Landdry ML, Pfaller MA, editors. Antifungal agents. Manual of clinical microbiology. 2008. 9th ed. Washington, DC: ASM Press;1949.

2. Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008. 46:120–128.

3. Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoam Micol. 2008. 25:101–106.

4. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004. 42:4419–4431.

5. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002. 2:73–85.

6. Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, Lee WG, Lee HS, Chang CL, Kim SH, Shin MG, Suh SP, Ryang DW. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J. 2007. 48:779–786.

7. Shin JH, Chae MJ, Song JW, Jung SI, Cho D, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia. J Clin Microbiol. 2007. 45:2385–2391.

8. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005. 49:668–679.

9. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E. Global Antifungal Surveillance Study. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007. 45:1735–1745.

10. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006. 19:435–447.

11. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol. 2004. 42:3142–3146.

12. Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, Uh Y, Lee HS, Lee MK, Jeong SH, Jung SI, Park KH, Lee JS, Shin MG, Suh SP, Ryang DW. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol. 2009. 47:296–304.

13. Pfaller MA, Messer SA, Hollis RJ, Jones RN. SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002. 46:1032–1037.

14. Shin JH, Park M, Song JW, Shin DH, Jung SI, Park YK, Shin MG, Cho D, Kee SJ, Suh SP, Ryang DW. In-Vitro Susceptibilities of Voriconazole Against Korean Clinical Aspergillus Isolates. Korean J Med Mycol. 2004. 9:166–173.

15. Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents. 2007. 30:487–495.

16. Siwek GT, Pfaller MA, Polgreen PM, Cobb S, Hoth P, Magalheas-Silverman M, Diekema DJ. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagn Microbiol Infect Dis. 2006. 55:209–212.

17. Park JY, Shin JH, Uh Y, Kim EC, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. In Vitro Amphotericin B Susceptibility of Korean Bloodstream Yeast Isolates Assessed by the CLSI Broth Microdilution Method, Etest, and Minimum Fungicidal Concentration Test. Korean J Lab Med. 2008. 28:346–352.

18. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, Edwards JE. Infectious Diseases Society of America. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004. 38:161–189.

19. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, Lee JS, Jung SI, Park KH, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis. 2009. 48:e57–e61.

20. Arikan S, Has-elik G. Comparison of NCCLS microdilution method and Etest in antifungal susceptibility testing of clinical Trichosporon asahii isolates. Diagn Microbiol Infect Dis. 2002. 43:107–111.

21. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol. 2006. 44:1782–1787.

22. Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell. 2005. 4:625–632.

23. Lass-Flörl C, Kofler G, Kropshofer G, Hermans J, Kreczy A, Dierich MP, Niederwieser D. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother. 1998. 42:497–502.

24. Espinel-Ingroff A, Pfaller MA. Murray PR, Baron EJ, Jorgensen JH, Landdry ML, Pfaller MA, editors. Susceptibility test methods: yeasts and filamentous fingi. Manual of clinical microbiology. 2008. 9th ed. Washington, DC: ASM Press;1972.

25. Cheung C, Guo Y, Gialanella P, Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection. 2006. 34:345–348.

26. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007. 20:133–163.

27. Choi HW, Shin JH, Lee JS, Cho D, Shin MG, Suh SP, Ryang DW. In vitro susceptibilities to caspofungin and micafungin of clinical isolates of Candida species. Korean J Lab Med. 2006. 26:275–281.

28. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006. 50:2058–2063.

29. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis. 2006. 42:753–757.

30. Clinical and Laboratory Standards Institute. Approved standard M38-A2. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. 2008. 2nd ed. Villanova, Pa: Clinical and Laboratory Standards Institute.

31. Lee JS, Shin JH, Jung SI, Park KH, Choi HW, Cho D, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. In Vitro Susceptibilities of Clinical Isolates of Aspergillus Species against Echinocandins. Infect Chemother. 2007. 39:151–158.

32. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004. 48:3407–3411.

33. Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother. 2006. 50:3160–3161.